PRVL - Prevail Therapeutics Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
+0.05 (+0.43%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close 11.59
Open 11.53
Bid 11.35 x 1000
Ask 11.80 x 800
Day's Range 11.40 - 11.96
52 Week Range 9.83 - 16.90
Volume 63,083
Avg. Volume 318,833
Market Cap 395.726M
Beta (3Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -7.80
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 22.50
Trade prices are not sourced from all markets
  • Benzinga 5 days ago

    Analysts Initiate Bullish Coverage Of Prevail Therapeutics

    Ahmad said Prevail’s leading asset PR001 has a potentially large indication for treating Parkinson’s via disease-modifying therapy. PR001 could also potentially be the first therapy ever approved for treatment of neuronopathic Gaucher disease. In addition, Ahmad said PR006 for frontotemporal dementia and PR004 for synucleinopathies are also potential sources of long-term value creation for Prevail investors.

  • Benzinga 12 days ago

    FDA Grants Fast Track Designation For Prevail's Parkinson's Treatment

    Prevail Therapeutics (NASDAQ: PRVL) shares are trading higher after the company received FDA fast track designation for PR001 for the treatment of Parkinson's disease patients with a GBA1 mutation. “We are pleased that the FDA has granted Fast Track Designation for PR001, which underscores the unmet need of patients with Parkinson’s disease with a GBA1 mutation, a chronic and progressive neurodegenerative disorder that comprises 7% to 10% of the total Parkinson’s disease population worldwide,” said CEO Asa Abeliovich.

  • GlobeNewswire 12 days ago

    Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Parkinson’s Disease Patients with a GBA1 Mutation

    Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the Company’s lead gene therapy program, PR001, for the treatment of Parkinson’s disease patients with a GBA1 mutation (PD-GBA). PR001 is a potentially disease-modifying, single-dose, AAV9-based gene therapy being developed for the treatment of PD-GBA and neuronopathic Gaucher disease.

  • Benzinga last month

    Prevail Therapeutics Opens Below IPO Price

    New York-based Prevail Therapeutics (NASDAQ: PRVL ) opened for trade Thursday afternoon at $15.31 per share. The 7.353-million share IPO was priced at $17. Prevail is a gene therapy company founded in ...

  • Business Wire last month

    Prevail Therapeutics Announces Pricing of Initial Public Offering

    Prevail Therapeutics Inc. , a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced the pricing of its initial public offering of 7,353,000 shares of its common stock at a price to the public of $17.00 per share.

  • Benzinga last month

    Prevail Therapeutics IPO: What You Need To Know

    Want to partake in the gene therapy revolution that is emerging as a new paradigm in drug development? New York-based Prevail Therapeutics is planning a 7.353-million share IPO, estimated to be priced between $16 and $18, according to the S-1/A filing from June 10. The company has applied for listing its shares on the Nasdaq under the ticker symbol PRVL.

  • Benzinga last month

    IPO Outlook For The Week: Biotechs And A Grocery Outlet

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Stoke Therapeutics, Inc. (STOK) will issue 6.7 million shares between ...